首页 > 市场调查报告书 > 製药

市场调查报告书

商品编码

1820532

全球囊性纤维化治疗市场研究报告 - 产业分析、规模、份额、成长、趋势及预测（2025 年至 2033 年）

Global Cystic Fibrosis Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

出版日期: 2025年09月01日 | 出版商:

Value Market Research | 英文 129 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球囊性纤维化治疗市场预测将大幅成长，预计到 2033 年市场规模将飙升至 743.1 亿美元，较 2024 年的 194.3 亿美元大幅成长。这一扩张反映了 2025 年至 2033 年期间预计的 16.07% 的惊人年复合成长率(CAGR)。

随着精准医疗和基因编辑技术的出现，囊性纤维化治疗市场正在快速发展。针对CFTR蛋白的新型调节因子正在彻底改变治疗模式，提供更佳的疗效和个人化的治疗方案。生物标记驱动的诊断与即时患者监测的结合正在改善临床疗效，并促成自适应治疗策略。未来的发展预计将侧重于联合疗法和针对潜在基因突变的下一代基因疗法，预计将囊性纤维化从慢性疾病转变为可控製或可治癒的疾病。

基于RNA的疗法和CRISPR-Cas9基因编辑的新兴研究有望带来持久干预，在分子层面上纠正基因缺陷。病患登记和资料分析平台的扩展正在加速药物开发和上市后监测。此外，包括可吸入製剂和奈米载体在内的药物传输系统的进步正在提高生物利用度和患者依从性。随着治疗格局的演变，市场将见证生物技术创新者和医疗保健提供者之间日益加强的合作，从而推动创新并扩大尖端治疗的可及性。

我们的报告经过精心设计，旨在为客户提供关于各个行业和市场的全面且切实可行的洞察。每份报告都包含几个关键部分，以确保客户全面了解市场格局：

市场概况：对市场的详细介绍，包括定义、分类和行业现状概述。

市场动态：深入分析影响市场成长的关键驱动因素、限制因素、机会与挑战。本部分探讨技术进步、监管变化和新兴趋势等因素。

細項分析：根据产品类型、应用、最终用户和地理位置等标准，将市场细分为不同的细分市场。此分析重点在于突出每个细分市场的表现和潜力。

竞争格局：对主要市场参与者的全面评估，包括其市场份额、产品组合、策略倡议和财务表现。本部分深入分析了领先公司的竞争动态和关键策略。

市场预测：根据历史资料和当前市场状况，对特定时期的市场规模和成长趋势进行预测。这包括定量分析和图形表示，以说明未来的市场发展轨迹。

区域分析：评估不同地理区域的市场表现，确定关键市场和区域趋势。这有助于了解区域市场动态和机会。

新兴趋势与机会：识别当前及新兴市场趋势、技术创新和潜在投资领域。本部分提供对未来市场发展和成长前景的洞察。

涵盖的细分市场列表

囊性纤维化治疗市场报告的这一部分提供了国家和地区层面的详细资料，从而帮助策略家确定相应产品或服务的目标人群以及即将到来的机会。

按药物类别

CFTR调节剂
胰酵素补充剂
黏液溶解剂
支气管扩张剂

依给药途径

口服
吸入

按配销通路

医院药房
零售药局
网路药局
报告中介绍的公司列表
AbbVie Inc.、F. Hoffmann-La Roche Ltd、Gilead、Novartis AG、Vertex Pharmaceuticals Incorporated、AIT（先进吸入疗法）、Alaxia、Teva Pharmaceutical Industries Ltd.、Merck & Co. Inc.、Sionna Therapeutics、Alcresta Therapeutics Inc.、AstraZeneca.

如果您有任何客製化需求，请联络我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美各细分市场销售分析
- 北美各国销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲各细分市场销售分析
- 欧洲各国销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区分部销售分析
- 亚太地区国家销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲各细分市场销售分析
- 拉丁美洲各国销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲分部销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东和非洲其他地区销售分析

第九章：囊性纤维化治疗公司的竞争格局

囊性纤维化治疗市场竞争
伙伴关係/合作/协议
併购
新产品发布
其他发展

第十章：公司简介

顶级公司市占率分析
市场集中度
AbbVie Inc.

公司概况
公司收入
产品
最新动态

F. Hoffmann-La Roche Ltd

公司概况
公司收入
产品
最新动态

Gilead

公司概况
公司收入
产品
最新动态

Novartis AG

公司概况
公司收入
产品
最新动态

Vertex Pharmaceuticals Incorporated

公司概况
公司收入
产品
最新动态

AIT (Advanced Inhalation Therapies)

公司概况
公司收入
产品
最新动态

Alaxia

公司概况
公司收入
产品
最新动态

Teva Pharmaceutical Industries Ltd.

公司概况
公司收入
产品
最新动态

Merck & Co. Inc.

公司概况
公司收入
产品
最新动态

Sionna Therapeutics

公司概况
公司收入
产品
最新动态

Alcresta Therapeutics Inc.

公司概况
公司收入
产品
最新动态

AstraZeneca

公司概况
公司收入
产品
最新动态

注意 - 在公司简介中，财务细节和最新发展取决于可用性，或者在私人公司的情况下可能不涵盖

简介目录图表

Product Code: VMR112116811

The forecast for the Global Cystic Fibrosis Therapeutics market predicts substantial growth, with market size projected to soar to USD 74.31 Billion by 2033, a significant increase from the USD 19.43 Billion recorded in 2024. This expansion reflects an impressive compound annual growth rate (CAGR) of 16.07% anticipated between 2025 and 2033.

The cystic fibrosis therapeutics market is advancing rapidly with the advent of precision medicine and gene-editing technologies. Novel modulators targeting the CFTR protein are revolutionizing treatment paradigms, offering improved efficacy and personalized therapeutic regimens. The integration of biomarker-driven diagnostics and real-time patient monitoring is enhancing clinical outcomes and enabling adaptive treatment strategies. Future developments are expected to focus on combination therapies and next-generation gene therapies that address the underlying genetic mutations, potentially transforming cystic fibrosis from a chronic condition to a manageable or curable disease.

Emerging research in RNA-based therapeutics and CRISPR-Cas9 gene editing holds promise for durable interventions that correct genetic defects at the molecular level. The expansion of patient registries and data analytics platforms is facilitating accelerated drug development and post-market surveillance. Additionally, advancements in drug delivery systems, including inhalable formulations and nanocarriers, are improving bioavailability and patient compliance. As the therapeutic landscape evolves, the market will witness increased collaboration between biotech innovators and healthcare providers, driving innovation and expanding access to cutting-edge treatments.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Cystic Fibrosis Therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

CFTR Modulators
Pancreatic Enzyme Supplements
Mucolytics
Bronchodilators

By Route of Administration

Oral
Inhaled

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
List of Companies Profiled in the report
AbbVie Inc., F. Hoffmann-La Roche Ltd, Gilead, Novartis AG, Vertex Pharmaceuticals Incorporated, AIT (Advanced Inhalation Therapies), Alaxia, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Sionna Therapeutics, Alcresta Therapeutics Inc., AstraZeneca

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CYSTIC FIBROSIS THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Route of Administration
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET ANALYSIS BY DRUG CLASS

5.1. Overview By Drug Class
5.2. Historical and Forecast Data Analysis By Drug Class
5.3. CFTR Modulators Historic and Forecast Sales By Regions
5.4. Pancreatic Enzyme Supplements Historic and Forecast Sales By Regions
5.5. Mucolytics Historic and Forecast Sales By Regions
5.6. Bronchodilators Historic and Forecast Sales By Regions

6. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1. Overview By Route of Administration
6.2. Historical and Forecast Data Analysis By Route of Administration
6.3. Oral Historic and Forecast Sales By Regions
6.4. Inhaled Historic and Forecast Sales By Regions

7. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1. Overview By Distribution Channel
7.2. Historical and Forecast Data Analysis By Distribution Channel
7.3. Hospital Pharmacies Historic and Forecast Sales By Regions
7.4. Retail Pharmacies Historic and Forecast Sales By Regions
7.5. Online Pharmacies Historic and Forecast Sales By Regions

8. GLOBAL CYSTIC FIBROSIS THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CYSTIC FIBROSIS THERAPEUTICS COMPANIES

9.1. Cystic Fibrosis Therapeutics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF CYSTIC FIBROSIS THERAPEUTICS INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. AbbVie Inc.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. F. Hoffmann-La Roche Ltd
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Gilead
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Novartis AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Vertex Pharmaceuticals Incorporated
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. AIT (Advanced Inhalation Therapies)
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Alaxia
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. Teva Pharmaceutical Industries Ltd.
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Merck & Co. Inc.
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Sionna Therapeutics
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Alcresta Therapeutics Inc.
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. AstraZeneca
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments